ADHD extended-release tablets approved by FDA
FDA approval has been granted to new generic ADHD extended-release tablets from Mallinckrodt.
Pharmaceuticals business Mallinckrodt has received approval from the US Food and Drug Administration for the manufacturing and marketing of a generic version of Concerta tablets for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
The methylphenidate HCI extended-release tablets will be produced in 27, 36 and 54mg dosage strengths, with the 27mg tablets to be launched immediately.
Such tablets are used for the treatment of ADHD in children aged six years and above, as well as adolescents and adults with the condition up to the age of 65.
Mallinckrodt said that it holds separate 180-day exclusivity periods for each of the dosage strengths starting from their respective commercial launches. With that in mind, it intends to have the 36mg and 54mg tablets available commercially by the end of the first calendar quarter of 2013.
It is also currently applying for approval of an 18mg dosage strength methylphenidate HCI extended-release tablet.
Mark Trudeau, president of the company, said: "This approval represents an important addition to our line of generic pharmaceutical products and we look forward to providing an affordable treatment option to patients coping with ADHD.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.